Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 10c, Beats on Revenue
August 12, 2025 4:02 PM EDTLineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.13), $0.10 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $2.77 million versus the consensus estimate of $1.48 million.
For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.
... More